Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Solid Tumor × BID protein, human × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Tumor 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Breast Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Advanced Solid Tumor 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 8 Injections 8 tislelizumab 7 Nivolumab 3 Irinotecan 3 Gemcitabine 3 Cisplatin 3 Cetuximab 3 toripalimab 2 spartalizumab 2 olaparib 2 glumetinib 2 apatinib 2 adagrasib 2 Therapeutics 2 Paclitaxel 2 PM 01183 2 Midazolam 2 Leucovorin 2 Fluorouracil 2 Drug Therapy 2 Digoxin 2 Cyclophosphamide 2 Carboplatin 2 Capecitabine 2 Bupropion 2 Bevacizumab 2 Bendamustine Hydrochloride 2 zimberelimab 1 trastuzumab deruxtecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06560632 2026-01-16

POLAR

Repare Therapeutics

Phase 1 Terminated

26 enrolled 14 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡